ERBB2 and breast carcinoma: The in vivo results showed the inhibition of phosphoinositide 3-kinase (PI3K)/Akt/Forkhead box O-signaling pathway [91], and apigenin reduced Her2/neu protein expression in breast cancer mice models [92].